Lead Investigator

At Bristol Myers Squibb, we transform patients’ lives through science. As Lead Investigator you will drive the clinical evidence that decides whether a molecule becomes a medicine. Your work will shape protocols, protect participants, and accelerate decisions that reach people living with serious disease.

Performance Objectives

• Design and lock high-quality protocols within 90 days of concept approval so first-patient-in occurs on or ahead of timeline.
• Deliver complete, audit-ready data packages that enable go/no-go decisions at every stage-gate with zero critical GCP findings.
• Reduce screen-failure and dropout rates by 15 % versus historical benchmarks through site selection, training, and real-time risk-based monitoring.
• Lead cross-functional study teams (clinical operations, biostats, safety, regulatory) to hit all primary and secondary endpoints on time and on budget.
• Publish or present at least two peer-reviewed outputs per year that influence treatment guidelines or next-generation trial design.
• Mentor two emerging investigators to independent study-lead status within 18 months.

Environment & Resources

You report to the Head of Clinical Development. You will work with a dedicated study team, global CRO partners, and BMS’s integrated data and digital platforms. Travel is 20–25 % to sites and investigator meetings. You have authority to allocate study budget and to escalate safety or quality issues directly to the Development Leadership Team.

Essential Qualifications

• MD, DO, or equivalent plus 7+ years of industry-sponsored clinical research, including at least three studies as primary or lead investigator.
• Demonstrated success delivering Phase 2/3 trials in oncology, immunology, or cardiovascular disease that met or exceeded enrollment and data-quality targets.
• Deep working knowledge of ICH-GCP, FDA/EMA regulations, and risk-based quality management.
• Proven ability to translate scientific questions into executable protocols and to defend them with regulators and ethics committees.
• Track record of building high-performing, geographically dispersed investigator networks.

Role Selling Points

• Direct impact on BMS’s late-stage pipeline—molecules that already have Breakthrough Therapy or PRIME designations.
• Access to proprietary digital tools that cut query rates and accelerate database lock.
• Culture that rewards scientific courage: we publish negative as well as positive results.
• Competitive compensation, equity, and a benefits package designed for people who put patients first.

If you are ready to lead the studies that change lives, apply now. Patients are waiting.